NewGenIvf Group Ltd (NIVF) added an operating and financial review with unaudited results for the six months ended June 30, 2026. Revenue was US$1,924,881, down from US$2,019,628; IVF treatment revenue was US$1,574,320 and fertility referrals contributed US$350,561. Gross profit increased to US$464,488 from US$313,804, while gross margin rose to 24.1% from 15.5%; the review attributes the margin improvement mainly to Kyrgyzstan’s shift from IVF clinic services to referrals.
The company recorded a net loss of US$8,079,392, compared with net income of US$698,032 a year earlier. Net other expense was US$3,990,911, including a US$3,421,643 repurchase and forbearance agreement loss. Operating cash outflow was US$4,607,447; cash was US$1,023,789 and working capital surplus US$618,325 as of June 30, 2026. The company effected a 1-for-8 reverse stock split on October 26, 2026.
NewGenIvf Group Limited approved a reverse stock split of its issued and unissued shares at a ratio of one share for every eight shares, or as otherwise determined by its CEO. No shareholder vote, consent or approval is required or will be sought.
The split takes effect at 12:01 a.m. ET on October 23, 2026, when Class A Ordinary Shares are expected to begin trading on a split-adjusted basis. Based on outstanding Class A Ordinary Shares as of October 21, 2026, the count is expected to decline from approximately 9,821,197 to approximately 1,227,650; the actual count may be greater on the effective date because of convertible note exercises. Holders entitled to a fractional share at the participant level will receive one full post-split share. Options, warrants and other convertible securities will have their exercisable or convertible share counts divided by eight, subject to rounding to the nearest whole share.
NewGenIvf Group Ltd reported unaudited results for the six months ended June 30, 2026, with revenue of $1,924,881, compared with $2,019,628 for the six months ended June 30, 2025. Gross profit was $464,488, compared with $313,804. The company reported a net loss of $8,079,392, versus net income of $698,032; net loss attributable to the company’s shareholders was $8,035,306, compared with net income attributable to shareholders of $724,975.
As of June 30, 2026, cash and cash equivalents were $1,023,789, total assets were $36,436,970 and total liabilities were $10,723,608. Current liabilities totaled $10,508,521, including a $6,881,250 Repurchase Forbearance liability. The balance sheet listed 1,152,607 ordinary shares issued and outstanding as of June 30, 2026, versus 26,736 as of December 31, 2025.
NewGenIvf Group Limited (NIVF) approved a reverse stock split of its issued and unissued shares at a stated ratio of one post-split share for every four shares, or as otherwise determined by its Chief Executive Officer. The split takes effect at 12:01 a.m. ET on October 12, 2026, and Class A ordinary shares will begin split-adjusted trading on the Nasdaq Capital Market at market opening that day. Based on Class A shares outstanding on October 6, the company expects the split to reduce the count from approximately 35,688,329 to approximately 8,922,083; the actual count may be greater on the Record Date due to share issuances from convertible note exercises. No fractional shares will be issued; a holder otherwise entitled to a fraction will receive one full post-split share at the participant level. Options, warrants and other convertible securities outstanding immediately before the split will have their underlying share counts divided by four, subject to rounding to the nearest whole share.
NewGenIvf Group Ltd (NIVF) reported that directors Wing Fung Alfred Siu and Hei Yue Tina Fong each exercised 139,811 post-reverse-split options on October 5, 2026, at US$0.0001 per share; the company issued each director 139,811 Class B ordinary shares. The 279,622 options were exercised in total, and issuance followed settlement through requested debits to the directors’ current accounts and compliance with applicable laws and company policies.
Each director was granted options to acquire 73,647 and 272,140 pre-split Class B shares on July 8 and August 17, 2026, respectively, for no consideration. NewGenIvf effected a 1-for-3 reverse stock split on September 1, 2026. As of October 5, 2026, each reported 292,265 Class B shares beneficially owned with shared voting and dispositive power; the stated holdings consisted of 146,132 shares held by Siu and 146,133 by Fong. Their reported 0.8% was calculated using 35,131,425 Class A and 292,265 Class B shares issued and outstanding as of October 5, 2026. They said they hold the Class B shares to retain control of the issuer.
NewGenIvf Group Ltd (NIVF) Chairman & CEO Wing Fung Alfred Siu exercised vested stock options on October 5, 2026, acquiring 139,811 Class B Ordinary Shares at $0.0001 per share. The options were granted under the issuer’s 2024 Share Incentive Plan and agreements dated July 8 and August 17, 2026. His reported direct holdings after the transaction were 146,132 Class B Ordinary Shares. Reported share amounts reflect two 1-for-3 reverse stock splits implemented on July 6 and September 1, 2026; the post-transaction amount includes 6,321 historically held shares, adjusted from 56,881 pre-split shares.
NewGenIvf Group Ltd (NIVF) Chief Marketing Officer Hei Yue Tina Fong exercised vested stock options on October 5, 2026, acquiring 139,811 Class B Ordinary Shares at an exercise price of $0.0001 per share. Her reported resulting position was 146,133 Class B Ordinary Shares. The share amounts reflect two 1-for-3 reverse stock splits implemented on July 6, 2026, and September 1, 2026.
NewGenIVF Group Limited (NIVF) confirmed it had 27,287,002 issued and outstanding Class A ordinary shares at the close of business on October 1, 2026. The company said the count followed share issuances connected with a best efforts offering announced September 30, 2026, conversions of certain outstanding convertible promissory notes by certain holders, and share issuances under its equity line of credit facility.
NewGenIvf Group Ltd (NIVF) closed a public offering on September 30, 2026, on a reasonable best efforts basis, generating approximately $1.25 million in gross proceeds before placement agent fees and offering expenses. The offering comprised 125,000 Class A ordinary shares and pre-funded warrants to purchase up to 17,732,143 Class A ordinary shares. The price was $0.07 per share and $0.06999 per warrant, with a $0.00001-per-share exercise price.
The pre-funded warrants are immediately exercisable and may be exercised until exercised in full. NewGen expects to use net proceeds, together with existing cash, for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in its cell-sorting business, and general corporate purposes. Aegis Capital Corp. acted as exclusive placement agent; NewGen agreed to pay it a cash fee equal to 8.0% of gross proceeds and reimburse certain expenses. Officers, directors and employees holding ordinary shares agreed, subject to customary exceptions, not to offer, sell or otherwise dispose of beneficially owned ordinary shares for 60 days following closing.
NewGenIvf Group Ltd (NIVF) is offering 125,000 Class A ordinary shares at $0.07 each and 17,732,143 pre-funded warrants, and registering 17,732,143 Class A shares issuable on exercise plus up to 4,364,044 shares for resale by Vanquish Funding Group Inc., White Lion Capital LLC, and Pacific Pier Capital II, LP. Each pre-funded warrant costs $0.06999, has a $0.00001 exercise price and is immediately exercisable subject to a beneficial ownership limitation; each warrant sold reduces the ordinary shares offered one-for-one.
The best-efforts offering has no minimum and may end at NewGenIvf’s discretion before September 30, 2026. Its terms list $1,250,000 in gross proceeds, $100,000 in placement-agent fees and $1,150,000 to NewGenIvf before expenses; NewGenIvf receives no proceeds from selling-securityholder resales. NewGenIvf reported 2025 revenue of $4,726,433 versus $5,433,375 in 2024 and net income of $9,728,723 versus a $474,101 net loss. It also reports $6,262,500 in committed but unpaid consideration for an 11% PredicXion stake and identifies a risk that it may not continue as a going concern.